AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Total Debt

Last Annual Value

96.96M

3-Year CAGR

486%

5-Year CAGR

57%

10-Year CAGR

29%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Total Debt

SPRY · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
96.96M
607.3%60.8%N/A 
4.19M
-21.7%-26.0%-10.0%
SVRA logo
Savara Inc.
NASDAQ:SVRA
29.91M
4.1%3.0%20.9%
20.46M
6.0%24.4%10.8%
633.00K
N/A-46.8%N/A
350.00K
2.1%N/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
2.96M
-12.4%17.3%N/A
5.81M
-3.7%37.5%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
1.61M
-13.3%-35.5%34.5%
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07